1-(4-isobutylphenyl)-2-propanone | 64758-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-isobutylphenyl)-2-propanone
• 英文别名: 1-(4-isobutylphenyl)propan-2-one；4-isobutylphenylacetone；1-[4-(2-Methylpropyl)phenyl]propan-2-one
• CAS: 64758-89-0
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: DQVSPHVDHURYLJ-UHFFFAOYSA-N

物化性质

• 沸点：
  271.7±9.0 °C(Predicted)
• 密度：
  0.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-chlorobenzyl)-1-(4-methoxyphenyl)hydrazine 、 1-(4-isobutylphenyl)-2-propanone 在 溶剂黄146 作用下， 反应 24.0h， 以86%的产率得到1-(2-chlorobenzyl)-3-(4-isobutylphenyl)-5-methoxy-2-methyl-1H-indole
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS
  [FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À LA VOIE HEDGEHOG

  摘要：

  本文提供了规范中描述的式(I)、(II)、(III)、(IV)和(V)的新化合物，以及其药学上可接受的盐、溶剂化合物、前药和组合物，以及测量肿瘤细胞中刺猬途径激活、检查肿瘤细胞增殖、分化和凋亡的方法，以及使用所披露的化合物和药物组合物治疗与刺猬信号通路相关的疾病和疾病的方法。

  公开号：

  WO2020003119A1
• 作为产物：
  描述：

  异丁芬酸 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 生成 1-(4-isobutylphenyl)-2-propanone
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS
  [FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À LA VOIE HEDGEHOG

  摘要：

  本文提供了规范中描述的式(I)、(II)、(III)、(IV)和(V)的新化合物，以及其药学上可接受的盐、溶剂化合物、前药和组合物，以及测量肿瘤细胞中刺猬途径激活、检查肿瘤细胞增殖、分化和凋亡的方法，以及使用所披露的化合物和药物组合物治疗与刺猬信号通路相关的疾病和疾病的方法。

  公开号：

  WO2020003119A1

文献信息

• Quantitative relations between structure and activation of fibrinolysis in selected series of arylaliphatic acids
  作者：Miroslav Kuchař、Bohumila Brunová、Václav Rejholc、Magda Jelínková、Jiří Holubek、Oldřich Němeček

  DOI：10.1135/cccc19840122

  日期：——

  The paper describes the reaction of arylacetones IX with triethyl phosphonoacetate, producing esters of 4-aryl-3-methyl-2-butenoic acid, X, and 4-aryl-3-methyl-3-butenoic acid, X'. Their hydrolysis gave a mixture of the isomeric acids I and I', whose composition was investigated by ¹H NMR spectra. Also prepared were 3-methyl-3-phenyl-2-propenoic acids, II, 2-aryl-2-hydroxypropanoic acids, IV, and substituted α-benzyloxyphenylacetic acids, V. These acids, along with aryloxoaliphatic acids III, were investigated for efficacy in activation of fibrinolysis. The lipophilicites of the acids studied were determined either through the partition coefficients (acids Ia and IIa), using a system n-octanol-water (pH 3.5) or by partition chromatography. The experimental values of log Pwere compared with those calculated from the fragmental constants f and the parameters π. With the acids V the decrease in lipophilicity was similar to that observed with arylalkoxyaliphatic acids. With the acids, I, I' and II the fibrinolytic capacity was linearly proportional to lipophilicity. Although we evaluated fibrinolytic capacity of mixtures of the acids I and I', the linear relation was in agreement with that derived previously for a group of arylaliphatic acids. The presence of a functional group on the connecting chain in the acids III and IV had a negative effect on the fibrinolytic capacity. The decrease in fibrinolytic capacity might be due the functional groups being capable of forming hydrogen bonds.

  这篇论文描述了芳基醋酮IX与三乙基磷酸乙酯反应，生成4-芳基-3-甲基-2-丁烯酸酯X和4-芳基-3-甲基-3-丁烯酸酯X'。它们的水解产生了异构酸I和I'的混合物，其组成通过¹H NMR谱进行了研究。还制备了3-甲基-3-苯基-2-丙烯酸II，2-芳基-2-羟基丙酸IV和取代的α-苄氧基苯乙酸V。这些酸，连同芳基氧代脂肪酸III，被研究其在激活纤溶作用中的功效。所研究的酸的亲脂性通过分配系数（酸Ia和IIa）或通过分配色谱法在正辛醇-水（pH 3.5）体系中确定。实验值log P与从片段常数f和参数π计算得到的值进行了比较。对于酸V，亲脂性的降低类似于观察到的芳基氧代脂肪酸。对于酸I, I'和II，纤溶能力与亲脂性成正比。尽管我们评估了酸I和I'的混合物的纤溶能力，但线性关系与先前得出的一组芳基脂肪酸的结果一致。酸III和IV中连接链上的功能基团对纤溶能力有负面影响。纤溶能力的降低可能是由于功能基团能够形成氢键。
• Behaviour of Arylazo tert-Butyl Sulfides with Ketone Enolates. Competition between SRN1 α-arylation and Azocoupling Reactions.
  作者：Carlo Dell'Erba、Marino Novi、Giovanni Petrillo、Cinzia Tavani

  DOI：10.1016/s0040-4020(01)88144-8

  日期：——

  room temperature, with potassium acetone enolate to give good yields of 1-aryl-2-propanones via spontaneous SRN1 dark reactions, α-Phenylation of pinacolone and acetophenone enolates by 1a likewise occurs in excellent yields. In agreement with the involvement of an electron-transfer catalyzed chain process, the reaction of the 4-bromo derivative 1n with pinacolone enolate gives mainly the bis-substitution

  （Z）-芳基偶氮叔丁基硫化物1a-i在DMSO中和室温下与丙酮烯醇钾反应，通过自发的S RN 1暗反应，频哪酮的α-苯甲酰化反应生成1-芳基-2-丙烷的良好收率苯乙酮烯醇化1a的收率也很高。与电子转移催化链过程的参与相一致，4-溴衍生物1n与频哪酮烯醇酸酯的反应主要产生双取代产物13。在偶氮硫化物1j–m中，芳基化途径与碱基诱导的硫醇消除竞争，最终取决于偶氮硫化物的结构而导致吲唑8或11和/或2-氧代丙醛芳基腙9，10或12。
• METHOD OF PRODUCING A NOVEL OPIOID PEPTIDE
  申请人：LIPKOWSKI Andrej

  公开号：US20120004180A1

  公开（公告）日：2012-01-05

  The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased drug tolerance effects. The drugs may particularly be of use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatism, gout, neurodegenerative states, post-surgical and post-traumatic inflammations or ones induced by tumours.

  本发明声明了一种新结构的阿片肽的使用，除了具有药效团以外，还含有与速激肽受体反应的结构元素。由于阿片与附加元素的协同反应，获得了增强的镇痛活性，减少了药物耐受性效应，便于长期有效使用。该药物可特别用于治疗慢性疼痛，作为治疗风湿病、痛风、神经退行性疾病、手术后和创伤后炎症或肿瘤引起的炎症的有效镇痛剂。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Nishida Hidemitsu

  公开号：US20110059958A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下式（I）所描述的化合物，或其药学上可接受的盐或溶剂。本发明还提供了包含一种或多种所述化合物的制药组合物，并使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。